No Data
No Data
Sarepta Therapeutics Announces Leadership Change and Equity Deal
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Express News | Sarepta Therapeutics Inc - Approves $500 Million Share Repurchase Authorization